MRX-2843 clinical trials
Also written MRX-2843.
How each study uses MRX-2843 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the MRX-2843 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- MRX-2843
- 4
Studies by the year they started
4 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2021 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Meryx, Inc. (2) · Emory University (1) · Betta Pharmaceuticals Co., Ltd. (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test MRX-2843.
- Dec 2026MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung CancerPhase 1 · Emory University
Studies
Open first, then newest update. How each study uses MRX-2843 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung CancerRecruitingPhase 1Emory UniversityNCT04762199Written as Flt3/MerTK Inhibitor MRX-2843How we know
- Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPALRecruitingPhase 1Meryx, Inc.NCT04872478Written as MRX-2843How we know
- Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid TumorsCompletedPhase 1Meryx, Inc.NCT03510104Written as MRX-2843How we know
- A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid LeukemiaStatus unknownPhase 1/2Betta Pharmaceuticals Co., Ltd.NCT04946890Written as MRX2843How we know
Codes
What other systems call MRX-2843 · ClinicalTrials.gg INT001999
- MeSH (NLM) C000726164MRX-2843One source ClinicalTrials.gov
- UNII (FDA) 2MT30EHI63MRX-2843One source FDA
- NCI Thesaurus C151407Flt3/MerTK Inhibitor MRX-2843One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000726164 | MRX-2843 | One source ClinicalTrials.gov |
| UNII (FDA) | 2MT30EHI63 | MRX-2843 | One source FDA |
| NCI Thesaurus | C151407 | Flt3/MerTK Inhibitor MRX-2843 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.